Terms: = Kidney tumors AND BUB1B, BUBR1, 701, ENSG00000156970, SSK1, BUB1beta, MAD3L, hBUBR1, Bub1A, O60566
82 results:
1. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Beckermann KE; Asnis-Alibozek AG; Atkins MB; Escudier B; Hutson TE; Kasturi V; McDermott DF; Pal SK; Porta C; Rini BI; Verzoni E
Oncologist; 2024 Mar; 29(3):254-262. PubMed ID: 38262444
[TBL] [Abstract] [Full Text] [Related]
2. Functional variants of the chitinase 3-like 1 gene are associated with clinicopathologic outcomes and progression of prostate cancer.
Wen YC; Lin CY; Ho KH; Lin YW; Hsiao CH; Wang SS; Chang LC; Yang SF; Chien MH
J Cell Mol Med; 2023 Dec; 27(24):4202-4214. PubMed ID: 37902124
[TBL] [Abstract] [Full Text] [Related]
3. Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy.
Dong H; Cao Y; Jian Y; Lei J; Zhou W; Yu X; Zhang X; Peng Z; Sun Z
BMC Cancer; 2023 Oct; 23(1):943. PubMed ID: 37803307
[TBL] [Abstract] [Full Text] [Related]
4. [
Lin R; Wang C; Chen S; Lin T; Cai H; Chen S; Yang Y; Zhang J; Xu F; Zhang J; Chen X; Zang J; Miao W
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):535-547. PubMed ID: 37728667
[TBL] [Abstract] [Full Text] [Related]
5. [Establishment and validation of a novel nomogram to predict overall survival after radical nephrectomy].
Xiong LB; Zou XP; Ning K; Luo X; Peng YL; Zhou ZH; Wang J; Li Z; Yu CP; Dong P; Guo SJ; Han H; Zhou FJ; Zhang ZL
Zhonghua Zhong Liu Za Zhi; 2023 Aug; 45(8):681-689. PubMed ID: 37580273
[No Abstract] [Full Text] [Related]
6. Sugar-Sweetened and Artificially Sweetened Beverages and Risk of Liver Cancer and Chronic Liver Disease Mortality.
Zhao L; Zhang X; Coday M; Garcia DO; Li X; Mossavar-Rahmani Y; Naughton MJ; Lopez-Pentecost M; Saquib N; Shadyab AH; Simon MS; Snetselaar LG; Tabung FK; Tobias DK; VoPham T; McGlynn KA; Sesso HD; Giovannucci E; Manson JE; Hu FB; Tinker LF; Zhang X
JAMA; 2023 Aug; 330(6):537-546. PubMed ID: 37552302
[TBL] [Abstract] [Full Text] [Related]
7. Mediators of Black-White inequities in cardiovascular mortality among survivors of 18 cancers in the USA.
Sung H; Hyun N; Ohman RE; Yang EH; Siegel RL; Jemal A
Int J Epidemiol; 2024 Feb; 53(1):. PubMed ID: 37471575
[TBL] [Abstract] [Full Text] [Related]
8. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Pal SK; Albiges L; Tomczak P; Suárez C; Voss MH; de Velasco G; Chahoud J; Mochalova A; Procopio G; Mahammedi H; Zengerling F; Kim C; Osawa T; Angel M; Gupta S; Khan O; Bergthold G; Liu B; Kalaitzidou M; Huseni M; Scheffold C; Powles T; Choueiri TK
Lancet; 2023 Jul; 402(10397):185-195. PubMed ID: 37290461
[TBL] [Abstract] [Full Text] [Related]
9. Longitudinal Analysis of Cancer Risk in Children and Adults With Germline PTEN Variants.
Yehia L; Plitt G; Tushar AM; Joo J; Burke CA; Campbell SC; Heiden K; Jin J; Macaron C; Michener CM; Pederson HJ; Radhakrishnan K; Shin J; Tamburro J; Patil S; Eng C
JAMA Netw Open; 2023 Apr; 6(4):e239705. PubMed ID: 37093598
[TBL] [Abstract] [Full Text] [Related]
10. Identification of Differentially Methylated Genes Associated with Clear Cell Renal Cell Carcinoma and Their Prognostic Values.
Wan B; Yang Y; Zhang Z
J Environ Public Health; 2023; 2023():8405945. PubMed ID: 36793506
[TBL] [Abstract] [Full Text] [Related]
11. Renal arterial resistive index, monocyte chemotactic protein 1 and neutrophil gelatinase-associated lipocalin, for predicting acute kidney injury in critically ill cancer patients.
Córdova-Sánchez BM; Ñamendys-Silva SA; Pacheco-Bravo I; García-Guillén FJ; Mejía-Vilet JM; Cruz C; Barraza-Aguirre G; Ramírez-Talavera WO; López-Zamora AR; Monera-Martínez F; Vidal-Arellano LJ; Morales-Buenrostro LE
Int Urol Nephrol; 2023 Jul; 55(7):1799-1809. PubMed ID: 36753015
[TBL] [Abstract] [Full Text] [Related]
12. Simplified PADUA REnal (SPARE) Nephrometry System can Describe the Surgical Difficulty of Renal Masses With High Accuracy Even Without 3D Renal Models.
Watanabe T; Sadahira T; Sekito T; Maruyama Y; Edamura K; Kobayashi Y; Araki M
Urology; 2022 Dec; 170():132-138. PubMed ID: 36206826
[TBL] [Abstract] [Full Text] [Related]
13. Impact of Body Mass Index on Outcomes in an Asian population of Advanced Renal Cell Carcinoma and Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors.
Ishihara H; Ishiyama Y; Nemoto Y; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Clin Genitourin Cancer; 2023 Feb; 21(1):136-145. PubMed ID: 36031535
[TBL] [Abstract] [Full Text] [Related]
14. Performance of CT radiomics in predicting the overall survival of patients with stage III clear cell renal carcinoma after radical nephrectomy.
Han D; Yu N; Yu Y; He T; Duan X
Radiol Med; 2022 Aug; 127(8):837-847. PubMed ID: 35834111
[TBL] [Abstract] [Full Text] [Related]
15. Percutaneous microwave ablation under ultrasound guidance for renal cell carcinomas at clinical staging T1 in patients aged 65 years and older: A comparative study.
Cheng Z; Yu X; Han Z; Liu F; Yu J; Yang J; Ai D; Liang P
J Cancer Res Ther; 2022 Apr; 18(2):509-515. PubMed ID: 35645122
[TBL] [Abstract] [Full Text] [Related]
16. An evaluation of trends in the representation of patients by age, sex, and diverse race/ethnic groups in bladder and kidney cancer clinical trials.
Javier-DesLoges J; Nelson TJ; Murphy JD; McKay RR; Stewart TF; Kader AK; Derweesh I; Martinez ME; Rose BS
Urol Oncol; 2022 May; 40(5):199.e15-199.e21. PubMed ID: 35431133
[TBL] [Abstract] [Full Text] [Related]
17. Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach.
Li X; Shong K; Kim W; Yuan M; Yang H; Sato Y; Kume H; Ogawa S; Turkez H; Shoaie S; Boren J; Nielsen J; Uhlen M; Zhang C; Mardinoglu A
EBioMedicine; 2022 Apr; 78():103963. PubMed ID: 35339898
[TBL] [Abstract] [Full Text] [Related]
18. A novel nine-microRNA-based model to improve prognosis prediction of renal cell carcinoma.
Xu C; Zeng H; Fan J; Huang W; Yu X; Li S; Wang F; Long X
BMC Cancer; 2022 Mar; 22(1):264. PubMed ID: 35279104
[TBL] [Abstract] [Full Text] [Related]
19. PIWI-Interacting RNA Pathway Genes: Potential Biomarkers for Clear Cell Renal Cell Carcinoma.
Heng B; Xie X; Zeng W; Li H; Shi L; Ye W; Wu F
Dis Markers; 2022; 2022():3480377. PubMed ID: 35273654
[TBL] [Abstract] [Full Text] [Related]
20. Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer.
Krens SD; van Erp NP; Groenland SL; Moes DJAR; Mulder SF; Desar IME; van der Hulle T; Steeghs N; van Herpen CML
BMC Cancer; 2022 Mar; 22(1):228. PubMed ID: 35236333
[TBL] [Abstract] [Full Text] [Related]
[Next]
